Skip to main content
. 2021 Mar 13;22(6):2929. doi: 10.3390/ijms22062929

Table 6.

The effects of sulforaphane on cognitive impairment in Alzheimer’s disease (AD)-like animal models.

Model Sulforaphane Dose Findings Ref.
5×FAD mice every other day 10 mg/kg i.p. for 2 months ameliorated cognitive deficits (Morris water maze tests and passive avoidance tests) [31]
3×Tg-AD mice every other day 5 or 10 mg/kg i.p. for 2 months ameliorated cognitive deficits (Morris water maze tests) [31]
daily 10 or 50 mg/kg p.o.
6 days/week for 2 months
ameliorated memory deficit (novel object/location recognition tests and contextual fear conditioning tests) [34]
APP/PS1 mice daily 25 mg/kg p.o.
for 5 months
ameliorated cognitive dysfunction (open field and Morris water maze tests) [35]
PS1V97L mice daily 5 mg/kg i.p. for 4 months alleviated cognitive deficit (Morris water maze tests) [32]
AD-like mice induced by Aβ1–40 daily 30 mg/kg i.p. for 6 days ameliorated cognitive function (Y-maze and passive avoidance behavior tests) [36]
AD-like rat induced by Aβ42 daily 5 mg/kg i.p. for 7 days improved spatial learning [37]

i.p., intraperitoneally; p.o., per os (by mouth).